Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Treos Bio.

    Client Virtual Booth

    TREOS BIO

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Treos Bio
    unitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    The Harley Building, 79 New Cavendish Street, London W1W 6XB
    Telephone
    Telephone
    +44-20-3141 7370
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://treosbio.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Treos Bio Announces $14 Million Convertible Loan Note Financing

    Details:

    Proceeds will fund Phase II clinical trials of PolyPEPI-1018, the Company’s off-the-shelf polypeptide immunotherapy for metastatic colorectal cancer.


    Lead Product(s): PolyPEPI-1018

    Therapeutic Area: Oncology Product Name: PolyPEPI-1018

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Luminous Ventures

    Deal Size: $14.0 million Upfront Cash: Undisclosed

    Deal Type: Financing March 31, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine That Shows Broad T Cell Response

    Details:

    PolyPEPI-SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant was safe in two mouse models and elicited highly specific, TH1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus.


    Lead Product(s): PolyPEPI-SCoV-2 peptide vaccine,Montanide ISA 51VG

    Therapeutic Area: Infections and Infectious Diseases Product Name: PolyPEPI-SCoV-2 peptide

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 19, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Treos Bio Forms New Subsidiary to Develop a Preventive COVID-19 Peptide Vaccine

    Details:

    Treos Bio has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.


    Lead Product(s): PolyPEPI-SCoV-2

    Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Treos Bio Reports Positive Final Results of Phase I/II Off-The-Shelf CRC Cancer Immunotherapy in 2020 ASCO Poster Presentation

    Details:

    Treos plans to conduct a randomized Phase II study of PolyPEPI1018 in maintenance therapy setting for first-line treatment of MSS mCRC, as well as a Phase I/II study in late-stage patients as an add-on to third-line therapy.


    Lead Product(s): PolyPEPI1018

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 29, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search